Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.

ABSTRACT:

Purpose

Inhibition of vascular endothelial growth factor (VEGF) is a promising strategy to treat retinal complications of diabetes. In contrast to VEGF-A binding ranibizumab, aflibercept also binds to other members of the VEGF family including VEGF-B, but potential effects of this factor on permeability and angiogenic processes are unclear. Therefore, we studied how VEGF-B variants as single agents or together with VEGF-A165 might affect proliferation, migration, or barrier function of retinal endothelial cells (REC). Also investigated was the normalization of REC properties with both VEGF-inhibitors to explore if additional targeting of VEGF-B is relevant.

Methods

Stimulation of proliferation or migration of immortalized bovine REC (iBREC) and disturbance of their barrier b

SUBMITTER: Deissler HL 

PROVIDER: S-EPMC4445774 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature